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icotine and its primary oxidative metabolites are
metabolized in part by glucuronidation. Genetic
variation in UGT isoenzymes that catalyze glucuronidation activity suggests that variation in
glucuronidation rate is in part genetically determined.
The relative contribution of genetic and environmental sources to individual differences in the rate of
glucuronidation of nicotine, cotinine, and trans-3′hydroxycotinine was estimated in a twin study of
nicotine pharmacokinetics. Glucuronidation rate was
defined using measures that either accounted for
variability in renal clearance or assumed the same
relative renal clearance of parent drug and glucuronide conjugate across individuals. The former
definition resulted in highly correlated nicotine and
cotinine glucuronidation measures that were substantially influenced by the combined effect of
additive (heritable) and non-additive (dominant and
epistatic) genetic effects. These findings suggest
that genetic variation in UGT isoenzymes that act in
additive and interactive ways is an important determinant of individual variability in nicotine and cotinine
metabolism via glucuronidation pathways.

N

Keywords: nicotine metabolism, glucuronidation, twins,
heritability

Nicotine and its primary metabolites cotinine and
trans-3′-hydroxycotinine (3HC) are metabolized in
part by glucuronidation by UDP-glucuronosyltransferase (UGT) isoenzymes (Figure 1) and are excreted
in urine as glucuronide conjugates (Hukkanen et al.,
2005). Glucuronide metabolites of nicotine, cotinine,
and 3HC account for on average 25%–30% of total
nicotine metabolites in urine (Benowitz et al., 1994;
Byrd et al., 1992; Ghosheh & Hawes, 2002). To investigate the source of interindividual variability in the
metabolism and clearance of nicotine we conducted a
twin study to elucidate the relative contributions of
genetic and environmental influences. Study subjects
underwent a 30-minute infusion of stable isotope-

labeled nicotine and its major metabolite, cotinine,
followed by an 8-hour in-hospital stay. Blood and
urine samples were taken at regular intervals for
analysis of nicotine, cotinine, and metabolites. In prior
publications we have presented similar analyses for
total and renal clearance of nicotine and cotinine, as
well as the metabolic clearance of nicotine to cotinine
(primarily mediated by CYP2A6) (Benowitz et al.,
2008; Swan et al., 2005). In the present study we
examine the heritability of nicotine, cotinine and 3HC
metabolism via glucuronidation. To the best of our
knowledge no prior published twin studies have examined the metabolism of any drug by glucuronidation
or other conjugation pathways.

Materials and Methods
The disposition kinetics of nicotine was measured in
110 monozygotic (MZ) and 29 dizygotic (DZ) twin
pairs recruited from the Northern California Twin
Registry (NCTR). The NCTR is a volunteer registry
created in 1995 through an extensive advertising campaign that included advertising in 19 newspapers, San
Francisco Bay area-wide movie theaters, and AM/FM
radio stations. Within 2.5 years, this campaign resulted
in the enrollment of a total of 1,054 twins, from which
twins for the present study were recruited. Contact is
maintained with NCTR twins via annual newsletters
and birthday cards. A 5-year NCTR anniversary-celebration party held in July 2000 increased enrollment to
1,765 individual twins. Enrollment continues to this
day and is done mostly through referrals by registered
twins and through the registry website. Currently, there
are over 2,700 twins registered with the NCTR.
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Figure 1
Metabolism of nicotine to cotinine and to trans-3 -hydroxycotinine and their respective glucuronide conjugates.

Stringent exclusion criteria for study participation
resulted in a healthy sample. Study methodology has
been described in detail (Swan et al., 2004). Briefly,
exclusion criteria included ages younger than 18 or
older than 65; obesity; pregnancy in women; use of
medications known to affect drug metabolism (anticonvulsants or barbiturates); past year history of a
host of medical conditions (e.g., uncontrolled hypertension or diabetes, liver or kidney disease, cancer,
heart disease, psychiatric illness); and discomfort with
venipuncture procedures.
After overnight fasting and overnight smoking
abstinence (for smokers), subjects were administered a
30-minute intravenous infusion of deuterium-labeled
nicotine (nicotine-d2) and its proximate metabolite
cotinine (cotinine-d4), which are isotopic variants
used to study kinetics and metabolism. Labeled compounds are necessary because individuals who use
tobacco already have considerable levels of nicotine
and cotinine in their bodies that would make measurement of clearance of unlabeled nicotine or cotinine
impossible. Doses ranged from 0.5 to 2.0 μg/kg/min
depending on smoking status and if a smoker, on the
screening plasma cotinine concentration. Participants
received 0.5 μg/kg/min if plasma cotinine levels were
50 ng/ml or lower (levels consistent with not smoking
or smoking five or fewer cigarettes per day), 1.0
μg/kg/min if plasma cotinine levels were 50–150 ng/ml
(levels consistent with smoking 5–15 cigarettes per
day); and 2.0 μg/kg/min if plasma cotinine levels were
> 150 ng/ml (levels consistent with smoking 15 or
more cigarettes per day). The dose was always based
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on the lower plasma cotinine level within a twin pair
so that both twins of pairs discordant for smoking
received the same dose.
Details on synthesis of labeled compounds, experimental procedures and analytical chemistry have been
described (Swan et al., 2004). Blood samples were
taken at frequent intervals during and after infusion.
Subjects voided prior to the start of the infusion and
then urine was collected over the ensuing 8 hours.
Pharmacokinetic analysis: The rates of glucuronidation of nicotine, cotinine and 3HC were
defined in two ways. One definition was based on the
ratio of the glucuronide to parent compound in 8 hour
urine samples (designated Nic-G-d2/Nic-d2, Cot-Gd4/Cot-d4, and 3HC-G/3HC-d4), which specifically
captures the glucuronidation pathway. The use of
these ratios assumes that everyone has the same relative renal clearance of parent drug and glucuronide
conjugate. The second definition was the ratio of the
amount of nicotine and cotinine glucuronide excreted
in the urine to area under the plasma concentration
time curve (AUC) of nicotine and cotinine over 8
hours of urine collection (designated Nic-G-d2/AUC
Nic-d2 and Cot-G-d4/ AUC Cot-d4). This definition
provides a broader measure of glucuronidation rate
that accounts, at least in part, for individual variability in renal clearance. Plasma concentrations of 3HC
were not measured therefore the broader definition of
glucuronidation rate for 3HC could not be computed.
Statistical Analysis

Twin method. In twin pairs reared together, trait phenotypic variance can be decomposed into the additive
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effects of genes (A), which contribute to twin pair similarity, to shared environmental effects common to
twin siblings (C), which also contribute to twin pair
similarity, and to nonshared environmental effects (E),
which index experiences unique to each twin as well
as measurement error and contribute to twin pair dissimilarity. Nonadditive genetic effects (D) also
contribute to twin pair similarity and index interaction of gene alleles at the same locus (dominance) or
at different loci (epistasis). Nonadditive genetic and
shared environmental effects are confounded in twin
studies and cannot be modeled simultaneously. In
models without nonadditive genetic effects, the correlation between MZ twins is rMZ = A + C, and that
between DZ twins is rDZ = 0.5A + C. A rMZ/rDZ ratio of
2 indicates a heritable trait and little to no importance
of shared environment. A contribution of shared environment results in greater similarity of DZ cotwins
relative to MZ cotwins and rMZ/rDZ < 2. The rMZ/rDZ is
close to 1 if shared environmental influences are
primary contributors to twin pair resemblance and
additive genetic effects are not important. In the case
of non-additive genetic effects, the MZ twin pair correlation is rMZ = A + D and that of DZ twin pairs is
rDZ = 0.5A+0.25D resulting in rMZ/rDZ > 2.
Biometric models. To identify the best models that fit
the data, we compared model fit between general and
nested models. The general model estimated all three
A, C (or D), and E variance components (‘ACE’ or
‘ADE’ models). The fit of nested genetic (‘AE’ or
‘AD’), shared environmental (‘CE’) or non-shared
environmental (‘E’) models was compared to that of
the general model using the likelihood ratio chi-square
difference test. A significant difference (p < .05) in the
–2 log likelihood (–2LL) statistics between the general
and nested models at the difference degrees of freedom
suggested deterioration of model fit of the nested
model, thus favoring the general model. Best model fit
was evaluated based on the chi-square difference test
and on model parsimony indicated by the Akaike
Information Criterion (Akaike, 1987) favoring the fit
of a model with fewer estimated parameters; smaller
or negative AIC indicates better model parsimony.
Models were fit to MZ and DZ twin pair raw data,
unadjusted, and adjusted for age, sex, body mass
index (BMI), race/ethnicity, current cigarette smoking,
and oral contraceptive use in women. The choice of
covariates was based on exploratory analysis and
earlier work showing a relationship between these
measures and nicotine metabolism variables (Benowitz,
Lessov-Schlaggar et al., 2006; Benowitz, Swan et al.,
2006). Biometric analyses were conducted using Mx
software (Neale et al., 2002).

pair had missing data on one of the variables due to
urine analyte levels below the limits of quantitation.
Sample demographics have been reported (Swan et al.,
2005). Here, sample demographics are shown by
zygosity (MZ vs. DZ) (Table 1). Overall, glucuronidation data were available from 109 MZ and 29 DZ
twin pairs comprising 74 MZ and 19 DZ female same
sex pairs, 35 MZ and 4 DZ male same sex pairs, and
6 DZ opposite sex pairs. MZ and DZ twins did not
significantly differ on demographic characteristic.
Group comparisons were conducted using logistic
regression (zygosity group was the dependent variable)
in STATA software (StataCorp, 2005). A robust estimator for standard errors was applied to adjust
estimates for data non-independence.
Geometric mean values for the metabolite ratios
are shown in Table 2 before and after removal of outliers > 3 SDs beyond sample means. Normal
distributions were achieved using either logarithmic
or square root transformation and the transformation
with the best skewness and kurtosis statistics for the
total sample as well as in MZ and DZ zygosity
groups were selected for biometric analysis.
Phenotypic correlations between metabolite ratios
are shown in Table 3. The ratio of 3HC-gluc-d4/3HC-d4
was not significantly correlated with Nic-G-d2/ Nic-d2
and had low, though statistically significant, correlations
with the other three metabolite ratios (r = 0.17–0.19).
Nic-G-d2/Nic-d2 was moderately correlated to Cot-Gd4/Cot-d4, Nic-G-d2/AUC Nic-d2, and Cot-G-d4/AUC
Cot-d4 (r = 0.42–0.57) and these latter three ratios were
strongly correlated with each other (r = 0.62–0.78).
MZ and DZ twin pair correlations and their ratios
are shown in Table 4. Three metabolite ratios had
rMZ /rDZ >2 suggesting the influence of non-additive
genetic factors and the other two twin pair correlation
ratios were close to 1, suggesting an important influ-

Table 1
Sample Demographic Characteristics
MZ twins
Mean (SD )
or %

n

Mean (SD )
or %

Age

218

37.7 (12.0)

58

37.8 (11.8)

Body weight (kg)

218

70.4 (14.0)

58

72.7 (11.9)

BMI (kg/m2)

218

24.9 (4.0)

58

25.4 (3.9)

Sex (% female)

218

67.9

58

75.9

Race/ethnicity
(% Caucasian)

218

76.2

58

75.9

Current smoker

218

17.4

58

Former smoker

Results
Of a total of 278 twins who underwent the infusion
protocol, one MZ pair had missing data on all glucuronidation measures. An additional five twins from
different MZ pairs and two twins from the same MZ

DZ twins

n

24.3

Never smoker
OC use in women (%)

58.3
148

27.7

OC use in women from DZ
female–male pairs (%)

29.3
24.1
46.6

44

22.7

6

50.0

Note: BMI = body mass index; OC = oral contraceptives.
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Full and reduced biometric models are shown in
Tables 5 and 6, before and after covariate adjustment,
respectively. In unadjusted models, consistent with the
pattern of twin pair correlations, variation in Cot-Gd4/Cot-d4 and 3HC–G/3HC-d4 was primarily
attributable to shared environmental factors. The ‘CE’
model was best fitting for Cot-G-d4/Cot-d4 since
dropping the shared environmental factor contributed
to significant deterioration of model fit (p = .042),
while dropping the additive genetic component did
not significantly change model fit (in fact a p value
for the difference –2LL between the ‘ACE’ and ‘CE’
models could not be estimated due to identical –2LL
estimates in the two models). For Nic-G-d2/Nic-d2
and Nic-G-d2/AUC Nic-d2, variance components estimates in the full ‘ADE’ models showed a relatively
greater contribution of nonadditive compared to additive genetic variance on phenotypic variability, while
additive genetic effects appeared more important for
Cot-G-d4/AUC Cot-d4. In every case, however, dropping the nonadditive component did not result in
significant deterioration of model fit, but dropping
both genetic components resulted in worsening of
model fit. This pattern of results suggests that, overall,
genetic effects are important contributors to individual
differences in Nic-G-d2/Nic-d2, Nic-G-d2/AUC Nicd2, and Cot-G-d4/AUC Cot-d4 metabolite ratios.
Biometric results did not change substantially after
covariate adjustment. Shared environmental factors
remained more important contributors to phenotypic
variance of Cot-G-d4/Cot-d4 and 3HC-G/3HC-d4
metabolite ratios, and additive and non-additive
genetic factors played a significant role on variance in
Nic-G-d2/Nic-d2, Nic-G-d2/AUC Nic-d2, and Cot-Gd4/AUC Cot-d4 metabolite ratios.

Table 2
Nicotine and Cotinine Glucuronide Metabolite Ratios

n

Mean

Nic-G-d2/Nic-d2

274

0.63

Cot-G-d4/Cot-d4

276

0.36

3HC-G-d4/3HC-d4

272

Nic-G-d2/AUC Nic-d2
Cot-G-d4/AUC Cot-d4

SD

Min

Max

0.70

0

3.99

0.28

0

1.56

0.16

0.10

0

0.60

275

13.92

10.52

0

67.35

276

3.00

2.52

0

17.19

Nic-G-d2/Nic-d2

266

0.55

0.52

0

2.38

Cot-G-d4/Cot-d4

269

0.34

0.23

0

1.19

3HC-G-d4/3HC-d4

269

0.15

0.09

0

0.42

Nic-G-d2/AUC Nic-d2

272

13.41

9.36

0

44.22

Cot-G-d4/AUC Cot-d4

271

2.80

2.07

0

10.22

No Outliers

Note: Nic-G-d2/Nic-d2, Cot-G-d4/Cot-d4, and 3HC-G/3HC-d4=ratio of nicotine, cotinine,
or 3HC glucuronide to parent compound in urine; Nic-G-d2/AUC Nic-d2 and CotG-d4/AUC Cot-d4 = ratio of nicotine or cotinine amount excreted in urine to area
under the plasma concentration time curve.

ence of shared environmental factors. All MZ twin
pair correlations were significant. Due to the small DZ
sample size (n = 26–29 pairs), three of five DZ twin
pair correlations were not statistically significantly different from zero. Based on the twin pair correlation
ratios, ‘ADE’ models were fit to data for Nic-gluc-d2/
Nic-d2, Nic-gluc-d2/AUC Nic-d2, and Cot-gluc-d4/
AUC Cot-d4, and ‘ACE’ models were fit to data for
Cot-gluc-d4/Cot-d4 and 3HC-gluc-d4/3HC-d4.
Because the sole influence of non-additive genetic
effects cannot exist without the background of overall
additive genetic effects, nested nonadditive ‘DE’
models were not considered.

Table 3
Correlations Between Metabolite Ratios
Nic-G-d2/Nic-d2 (log)

Cot-G-d4/Cot-d4 (log)

3HC-G-d4/3HC-d4 (log)

Nic-G-d2/AUC Nic-d2 (sqrt)

Nic-G-d2/Nic-d2 (log)

—

Cot-G-d4/Cot-d4 (log)

0.45 (0.35, 0.55)**

—

3HC-G-d4/3HC-d4 (log)

0.08 (-0.04, 0.20)

0.19 (0.08, 0.31)**

—

Nic-G-d2/AUC Nic-d2 (sqrt)

0.57 (0.48, 0.64)**

0.62 (0.54, 0.69)**

0.17 (0.05, 0.28)**

—

Cot-G-d4/AUC Cot-d4 (log)

0.42 (0.31, 0.51)**

0.78 (0.73, 0.82)**

0.19 (0.07, 0.30)**

0.78 (0.73, 0.82)**

Note: log = natural logarithm transformation; sqrt = square root transformation; numbers in parentheses are 95% confidence intervals; ** p < .01.

Table 4
Twin Pair Correlations

510

n pairs

rMZ (95% CI)

n pairs

Nic-G-d2/Nic-d2 (log)

100

0.32 (0.14, 0.49)

28

0.12 (–0.26, 0.47)

2.7

Cot-G-d4/Cot-d4 (log)

104

0.53 (0.47, 0.71)

26

0.45 (0.07, 0.71)

1.2

3HC-G-d4/3HC-d4 (log)

103

0.41 (0.24, 0.56)

28

0.52 (0.18, 0.75)

0.8

Nic-G-d2/AUC Nic-d2 (sqrt)

105

0.51 (0.36, 0.64)

29

0.05 (–0.33, 0.41)

10.2

Cot-G-d4/AUC Cot-d4 (log)

104

0.52 (0.36, 0.65)

29

0.20 (–0.18, 0.53)

2.6

Twin Research and Human Genetics October 2009

rDZ (95% CI)

rMZ /rDZ

Genetic Influences on Nicotine Glucuronidation

Table 5
Model Fitting Results for Nicotine Metabolite Ratios in Unadjusted Models
Model fit statistics

Model parameter estimates

Metabolite Ratios

Model

–2LL

df

AIC

Nic-G-d2/Nic-d2 (log)

ADE
AE
E

89.64
89.74
100.72

262
263
264

–434.36
–436.26
–427.28

ACE
CE
AE
E

–281.42
–281.42
–277.29
–225.20

265
266
266
267

ACE
CE
AE
E

–634.51
–634.51
–631.94
–607.69

ADE
AE
E
ADE
AE
E

Cot-G-d4/Cot-d4 (log)

3HC-G-d4/3HC-d4 (log)

Nic-G-d2/AUC Nic-d2 (sqrt)

Cot-G-d4/AUC Cot-d4 (log)

p diff

A (95% CI)

C or D (95% CI)

E (95% CI)

.754
.004

2.24 (0, 47.6)
31.8 (13.4, 47.7)
—

30.0 (0, 48.2)
—
—

67.8 (51.9, 86.3)
68.3 (52.3, 86.6)
100

–811.42
–811.42
–809.29
–759.20

uncalc
.042
< .001

0 (0, 57.3)
—
60.8 (47.9, 70.7)
—

61.8 (4.0, 71.5)
61.8 (49.4, 71.6)
—
—

38.2 (28.5, 50.6)
38.2 (28.5, 50.6)
39.3 (29.3, 52.1)
100

265
266
266
267

–1164.51
–1166.51
–1163.94
–1141.69

uncalc
.109
< .001

0 (0, 54.1)
—
45.9 (29.5, 59.4)
—

43.9 (0, 56.9)
44.0 (28.8, 56.9)
—
—

56.1 (42.1, 71.2)
56.1 (43.1, 71.2)
54.1 (40.6, 70.5)
100

855.73
856.68
887.73

268
269
270

320.68
318.68
347.73

.329
< .001

0 (0, 59.9)
48.8 (33.5, 61.4)
—

49.5 (0, 61.8)
—
—

50.5 (38.2, 65.5)
51.3 (38.6, 66.5)
100

378.31
378.31
412.70

267
268
269

–155.69
–157.69
–125.30

.976
< .001

49.1 (0, 63.5)
51.4 (36.5, 63.5)
—

2.4 (0, 63.1)
—
—

48.6 (36.5, 63.5)
48.6 (36.5, 63.5)
100

Note: –2LL = –2 times log likelihood; df=degrees of freedom; AIC = Akaike Information Criterion; p diff = p value for the chi-square difference test between the full model and
submodels; A, C, D, E = variance components estimates of additive genetic, shared environmental, nonadditive genetic, and individual-specific environmental factors;
uncalc = uncalculable p value due to zero or near zero –2LL difference between models. Model in italics provides the best fit to the data.

Table 6
Model Fitting Results for Nicotine Metabolite Ratios in Adjusted Models*
Model fit statistics

Model parameter estimates

Metabolite Ratios

Model

–2LL

df

AIC

Nic-G-d2/Nic-d2 (log)

ADE
AE
E

67.24
67.48
74.65

256
257
258

–444.76
–446.52
–441.35

.626
.025

ACE
CE
AE
E

–316.48
–316.31
–314.76
–263.18

259
260
260
261

–834.48
–836.31
–834.76
–785.18

.677
.190
< .001

ACE
CE
AE
E

–641.40
–641.45
–638.73
–618.60

259
260
260
261

–1159.40
–1161.45
–1158.73
–1140.60

ADE
AE
E

835.34
836.38
860.66

262
263
264

ADE
AE
E

357.41
357.46
383.61

261
262
263

Cot-G-d4/Cot-d4 (log)

3HC-G-d4/3HC-d4 (log)

Nic-G-d2/AUC Nic-d2 (sqrt)

Cot-G-d4/AUC Cot-d4 (log)

p diff

A (95% CI)

C or D (95% CI)

E (95% CI)

0 (0, 42.4)
26.0 (7.1, 42.8)
—

26.6 (0, 43.4)
—
—

73.4 (56.6, 92.3)
74.0 (57.2, 92.9)
100

11.8 (0, 68.7)
—
61.0 (48.1, 71.0)

48.8 (0, 69.7)
39.8 (47.1, 69.9)
—

39.4 (29.0, 52.6)
40.2 (30.1, 52.9)
39.0 (29.0, 51.9)
100

uncalc
.102
< .001

1.7 (1.6, 49.7)
—
42.6 (25.5, 56.8)
—

39.8 (1.5, 53.5)
41.2 (25.5, 54.8)
—
—

58.6 (44.6, 74.3)
58.8 (45.2, 74.5)
57.4 (43.2, 74.5)
100

311.34
310.38
332.66

.306
< .001

0 (0, 56.2)
44.4 (28.2, 58.0)
—

45.5 (0, 58.8)
—
—

54.5 (41.2, 70.5)
55.6 (42.0, 71.9)
100

–164.59
–166.54
–142.39

.821
< .001

30.1 (0, 59.9)
46.6 (30.4, 59.9)
—

16.7 (0, 60.0)
—
—

53.1 (39.8, 69.5)
53.4 (40.1, 69.6)
100

Note: See Table 5 footnote for explanations.
*Covariates = age, sex, BMI, race/ethnicity, current smoking, and oral contraceptive use in women.

Discussion
Prior research has identified a high correlation in the
ratios of glucuronide to parent drug between nicotine
and cotinine. Therefore, nicotine and cotinine glucuronidation is thought to occur via the same pathway
(Benowitz et al., 1994). Nicotine and cotinine glucuronidation appears to be catalyzed primarily by
UGT2B10 and UGT1A4 and to a minor extent by
UGT1A9 and UGT2B7 isoenzymes (Chen et al., 2007;

Kaivosaari et al., 2007; Kuehl & Murphy, 2003;
Nakajima et al., 1996). We expected, therefore, to
observe high correlations between nicotine and cotinine glucuronide metabolite ratios and similarity in
results in terms of genetic and environmental contribution to phenotypic variance.
Genetic variation in the UGT2B10 gene is associated
with reduced nicotine and cotinine glucuronidation
(Chen et al., 2007). Functional genetic variation has also
been identified in the UGT1A4, UGT1A9, and
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UGT2B7 genes (Argikar et al., 2008), and variant
UGT1A4 genotypes have been associated with reduction in glucuronidation of the tobacco-specific
nitrosamine NNAL (Ehmer et al., 2004). We expected,
therefore, that nicotine and cotinine glucuronide
metabolite ratios would be, at least in part, heritable
phenotypes.
Both expectations were met with respect to the
ratios of nicotine and cotinine excreted in the urine
relative to respective areas under the plasma concentration-time curve. These two ratio measures were
highly correlated (r = 0.78) and showed overall strong
genetic contribution (combined additive and non-additive genetic variance) even after controlling for a
number of covariates. The high estimate for non-additive genetic effects for Nic-G-d2/AUC Nic-d2 is due to
the very large rMZ/rDZ ratio resulting from a near zero
DZ twin pair correlation and a significant MZ twin
pair correlation. The small sample of DZ twin pairs
likely contributes to unreliable DZ twin pair correlation estimates, as also evidenced by the wide 95%
confidence intervals. The Northern California Twin
Registry from which twins for this study were
recruited, has about three times more MZ than DZ
twins, consistent with the zygosity distribution in this
study. DZ twin pairs have been much more difficult to
recruit to the registry. It is possible that because this is
a volunteer-based registry, DZ twin pairs do not feel
more alike than any two simblings and thus are less
willing to participate in a twin registry compared to
MZ twin pairs.
Because the relatively small number of DZ twin
pairs reduced power to detect nonadditive genetic
effects, ‘ACE’ models were also fit to Nic-G-d2/Nicd2, Nic-G-d2/AUC Nic-d2, and Cot-G-d4/AUC
Cot-d4 metabolite ratio data. The shared environmental estimate was zero in every case, and the additive
genetic estimate was 26%, 44.4%, and 46.5% in
adjusted models, respectively. The additive genetic
component could be dropped from all models without
deterioration of model fit, but the non-shared environmental models significantly worsened model fit. Taken
together, biometric analyses suggest a substantial
genetic contribution to individual variation in Nic-Gd2/AUC Nic-d2, and Cot-G-d4/AUC Cot-d4 (around
45% to 50% after combining the effects of additive
and nonadditive genetic effects), more modest genetic
contribution to variation in Nic-G-d2/Nic-d2 (around
30%), and largely shared environmental contribution
to variation in Cot-G-d4/Cot-d4 and 3HC-G-d4/3HCd4 metabolite ratios. Because renal clearances of
nicotine and cotinine are pH-dependent, it is likely
that variation in the metabolite ratios of Cot-Gd4/Cot-d4 and 3HC-G-d4/3HC-d4 is affected by urine
pH, which in turn can be affected by diet and fluid
intake. Thus the shared environmental influences
could indicate commonality in diet in twin siblings.
We do not have data on diet or on twin sibling cohabitation history, which could give some clues on
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likelihood of sharing dietary habits around the time of
study participation.
The moderate correlation between Nic-G-d2/Nicd2 and Cot-G-d4/Cot-d4 (r = 0.45) and differences in
biometric results are most likely related to individual
differences in the clearance of nicotine and cotinine in
relation to their glucuronide metabolites, based on
differences in urine pH and perhaps urine flow.
Identification of enzymes that catalyze nicotine and
cotinine glucuronidation is an active area of research
and it is also possible that there are as yet unidentified
proteins involved in glucuronidation of nicotine but
not cotinine or vice versa.
Glucuronidation of 3HC is primarily catalyzed by
UGT2B7 and to a lesser extent by UGT1A9 (Yamanaka
et al., 2005). 3HC glucuronidation represents a different glucuronidation pathway from that of nicotine and
cotinine as previously suggested (Benowitz et al., 1994)
and as supported by the results in this paper, which
show little to no correlation between the 3HC glucuronide ratio and either the nicotine or cotinine
glucuronide ratios. No association between functional
variants in either the UGT2B7 or UGT1A9 genes and
nicotine-related metabolism has been reported to date.
Glucuronidation is for most people a minor nicotine metabolism pathway, but plays a larger role in
nicotine metabolism in those who carry a slow metabolism variant allele of the polymorphic CYP2A6 gene
(Benowitz, Swan et al., 2006). Because 80% of nicotine is metabolized via the CYP2A6 pathway in those
with normal CYP2A6 activity (Hukkanen et al., 2005)
even a small decrease in metabolic rate via this major
pathway could have significant impact on the contribution of minor metabolic pathways.
In summary, our findings suggest that genetic variation in UGT isoenzymes that act in additive and
interactive ways is an important determinant of individual variability in nicotine and cotinine metabolism
via glucuronidation pathways, as assessed by the NicG-d2/AUC Nic-d2 and Cot-G-d4/AUC Cot-d4 ratios.
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